MURRYSVILLE, Pa., Oct. 26 /PRNewswire-FirstCall/ -- Respironics, Inc. today announced record financial results for the three months ended September 30, 2006.
FINANCIAL RESULTS
Three Months Ended September 30, 2006
Net sales for the first quarter totaled $266.6 million, up 11 percent over the $240.2 million achieved in the first quarter a year ago.
Domestic revenues increased 9 percent from $166.0 million in the first quarter a year ago to $181.6 million in the current year’s first quarter. The Company’s domestic revenue gains were led by a year-over-year increase of $14.4 million, or 15 percent, in domestic sleep therapy products. This increase in sleep therapy revenues was achieved as the Company continued to execute on its planned transition to the new M-Series platform of positive airway pressure devices. The Company’s Alice(R) 5 Sleep Diagnostics System continues to gain market share in sleep labs, posting $5.8 million of revenues in the first quarter which represents 41 percent year-over-year growth.
International revenues totaled $85.0 million for the first quarter, a 15 percent increase over the $74.2 million reported a year ago, led by 27 percent growth in the sleep therapy market. The Company also achieved 31 percent growth in its hospital products in the international markets. International revenues represented 32 percent of total revenues during the quarter.
On a global basis, sleep therapy revenues grew by 17 percent during the first quarter, from $131.1 million to $153.9 million. Global hospital ventilation sales grew by 14 percent, from $28.4 million to $32.3 million in the first quarter of fiscal year 2007.
Net income for the current quarter was $22.1 million, or $0.30 per diluted share, including stock compensation expenses totaling $3.0 million on a pre- tax basis, or $0.03 per diluted share after tax. This represents 18 percent earnings per share growth compared to the $0.25 per diluted share reported in the prior year first quarter. The prior year first quarter included $2.8 million of stock compensation expenses on a pre-tax basis, or $0.03 per diluted share after tax. Excluding the impact of stock compensation expense in the current year first quarter, net income was $24.2 million, or $0.33 per diluted share. This represents a 17 percent increase over the $0.28 per diluted share reported a year ago, excluding stock compensation expense.
During the current year first quarter the Company incurred $1.7 million of restructuring and acquisition-related expenses, primarily associated with the previously announced closure of its Galway, Ireland manufacturing facility and the integration of acquired companies. These expenses are included in the Company’s GAAP-basis $0.30 per diluted share and the $0.33 per diluted share excluding stock compensation expenses reported above.
The Company also noted that it expects to conduct a limited, voluntary product recall of a heated humidifier device used with its older legacy CPAP systems. The Company is currently in discussion with the FDA regarding this action and will finalize its proposed course of action after these conversations are completed. Included in the Company’s general and administration expense is an additional charge associated with this anticipated action. The Company has incorporated the anticipated impact of the recall into its fiscal year 2007 guidance. In total, the Company expects that approximately 172,000 humidifiers, produced three to five years ago, are affected, and it estimates a cost impact of approximately $5.0 million. This amount is accrued in the Company’s consolidated balance sheet as of September 30, 2006 and includes provisions that were made during the first quarter as well as prior periods, through warranty expense. The Company noted that these estimates and related accruals are all subject to FDA approval of the Company’s plan of action with respect to the recall.
The Company’s increase in earnings per share in the current year is primarily the result of sales growth and operating margin increases versus the prior year. With the financial information included in this press release, the Company provides a tabular reconciliation of GAAP net income with net income excluding the impact of stock compensation expenses.
COMMENTS FROM MANAGEMENT
Quarterly Results
John Miclot, President and Chief Executive Officer commented, “We are pleased to be reporting another quarter of record revenues and profits to begin our 2007 fiscal year. During the quarter, we continued our plan to transition to our new M-Series family of sleep therapy devices, and we are encouraged by the strong acceptance of these product offerings. As of the end of our first fiscal quarter, all models in the new series have been released, including our Bi-level devices which were introduced at the end of September. We would expect to complete the domestic transition by the end of the second quarter. On a global basis, our sleep therapy revenues increased by 17 percent. We also achieved another exceptional quarter of sleep diagnostic growth in the domestic marketplace, with growth in this segment exceeding 40 percent as we continue our focus on the sleep labs and clinical sleep medicine community. The Company is continuing its research and development efforts in the obstructive sleep apnea area and expects to release several new patient interfaces during fiscal year 2007.”
Mr. Miclot further stated, “During the quarter we introduced BiPAP(R) Focus(TM), our new non-invasive ventilation device for hospital use. This unit includes an improved clinician interface, smaller design and other enhancements for basic applications of non-invasive ventilation in the critical care setting. Also, in the hospital group during the quarter, our cardio-respiratory monitoring product line delivered strong growth as our CO2 monitoring technology continues to gain acceptance in hospitals and with our OEM customers.”
Commenting on the international marketplace, Mr. Miclot noted, “We continue to gain market share and momentum in the international sleep therapy market where we are progressing with our introduction of the M-Series. Clearance has been received and the product has been launched in nearly all major international markets. By the end of our second fiscal quarter, we expect the M-Series will have the necessary approvals and clearances for introduction into the remaining markets.”
Financial Position
The Company continues to maintain a strong balance sheet position, with $275.7 million of cash and marketable securities as of September 30, 2006, representing an increase of $10.4 million compared to June 30, 2006. During the quarter, the Company’s accounts receivable days sales outstanding was 64 days. The Company’s long-term debt balance was $26.3 million as of September 30, 2006. Respironics’ strong balance sheet positions the Company to execute its strategy which calls for optimizing the Company’s core growth drivers while investing in new areas of the sleep and respiratory markets. During the first quarter, the Company used $4.8 million for business acquisitions and strategic investments.
Outlook
For fiscal year 2007, the Company is comfortable with earnings per share estimates (exclusive of stock compensation expense) of approximately $1.73 to $1.77. Revenue expectations for the year are approximately $1,175 million to $1,190 million. Earnings per share estimates for the quarter ending December 31, 2006 are in the range of $0.42 to $0.43.
This earnings per share outlook does not include the impact of FASB No. 123(R). During the 2007 fiscal year, the Company expects to incur approximately $13.5 million to $14.5 million of stock compensation expense on a pre-tax basis, or $0.12 to $0.13 per share after tax. The Company expects to incur $3.5 million to $4.0 million of stock compensation expense on a pre-tax basis, or $0.03 to $0.04 per share after tax during the second quarter of the 2007 fiscal year. The actual expenses recorded during the 2007 fiscal year may fluctuate based on factors such as the actual number of equity awards granted to employees and changes in the Company’s stock price and interest rates.
Respironics is a leading developer, manufacturer and distributor of innovative products and programs that serve the global sleep and respiratory markets. Focusing on emerging market needs, the Company is committed to providing valued solutions to help improve outcomes for patients, clinicians and health care providers. Respironics markets its products in 131 countries and employs more than 4,700 associates worldwide. Further information can be found on the Company’s Web site: www.respironics.com.
The Company will host a conference call at 8:30 a.m. Eastern Time today to discuss these quarterly results, market trends and future outlook. The conference call will be broadcast live over the Internet and can be accessed by all interested parties from the Company’s web site at http://www.respironics.com or at http://www.companyboardroom.com. Please allow extra time prior to the call to visit the site and download the streaming media software required to listen to the Internet broadcast. A replay of the web cast will be available following the call.
FORWARD-LOOKING STATEMENT
This document contains forward-looking statements, including statements relating to, among other things, developments in the healthcare industry; the success of the Company’s marketing, sales, and promotion programs; future sales, acceptance, and quality of the Company’s products and programs; the timing and success of new product introductions; new product development; anticipated cost savings; FDA and other regulatory requirements, enforcement actions, product recalls or related field actions; future results from acquisitions and strategic investments; growth rates in foreign markets; regulations and other factors affecting operations and sales outside the United States; foreign currency fluctuations; the effects of a major earthquake, cyber-attack or other catastrophic event that results in the destruction or disruption of any critical business or information technology systems; customer consolidation and concentration; increasing price competition and other competitive factors in the manufacture, distribution, and sale of products; interest rate fluctuations; expiration of intellectual property rights; intellectual property and related litigation; other litigation; future levels of earnings and revenues; the number of equity awards granted to employees and changes in the Company’s stock price; and third party reimbursement; all of which are subject to change. Actual results may differ materially from those described in any forward-looking statements. Additional information on potential factors that could affect the Company’s financial results are included in the reports filed with the SEC, including the reports on Form 10-K, 10-Q and 8-K.
RESPIRONICS, INC. AND SUBSIDIARIES Condensed Statement of Operations & Reconciliation of Non-GAAP Financial Measures (Unaudited) (In thousands, except per share amounts) In managing its business, Respironics makes use of certain non-GAAP financial measures in evaluating the Company’s results of operations from core operations. The measure, “net income, excluding the impact of stock compensation expenses,” is reconciled with GAAP net income in the tables below: GAAP Non-GAAP 3 months 3 months Ended FAS 123(R) Ended Fiscal Year 2007 9/30/06 Impact 9/30/06 Sales $266,624 $266,624 Cost of goods sold 124,639 (170) 124,469 Gross profit 141,985 170 142,155 General & administrative expense 34,886 (2,015) 32,871 Sales, marketing, & commission expense 57,565 (662) 56,903 Research & development expense 14,513 (188) 14,325 Contribution to Foundation 0 0 Restructuring & acquisition- related expense 1,686 1,686 Other (income) / expense, net (1,985) (1,985) Net Income before income tax $35,320 $3,035 $38,355 Income tax 13,251 940 14,191 Net Income $22,069 $2,095 $24,164 Basic earnings per share 0.30 0.33 Basic shares outstanding 72,835 72,835 Diluted earnings per share 0.30 0.33 Diluted shares outstanding 73,710 418 74,128 GAAP Non-GAAP 3 months 3 months Ended FAS 123(R) Ended Fiscal Year 2006 9/30/05 Impact 9/30/05 Sales $240,222 $240,222 Cost of goods sold 107,543 (194) 107,349 Gross profit 132,679 194 132,873 General & administrative expense 41,551 (1,704) 39,847 Sales, marketing, & commission expense 50,506 (705) 49,801 Research & development expense 14,070 (170) 13,900 Contribution to foundation 1,500 1,500 Restructuring & acquisition- related expense 1,089 1,089 Other (income) / expense, net (5,937) (5,937) Net Income before income tax $29,900 $2,773 $32,673 Income tax 11,324 765 12,089 Net Income $18,576 $2,008 $20,584 Basic earnings per share 0.26 0.29 Basic shares outstanding 71,869 71,869 Diluted earnings per share 0.25 0.28 Diluted shares outstanding 73,341 360 73,701 Respironics believes that presenting diluted earnings per share, excluding the impact of stock compensation expenses, is an additional measure of performance that investors can use to compare operating results between reporting periods. Management of the Company uses this information in evaluating the Company’s results of operations and believes that this information may also provide investors better insight in evaluating the Company’s earnings performance from core operations in comparison to the prior year. Product Sales Summary (Unaudited) (Dollars in thousands) Three months ended 9/30/06 9/30/05 Domestic Sleep and Home Respiratory Group $138,258 $123,604 Domestic Hospital Group 43,337 42,404 International Group 85,029 74,214 Total $266,624 $240,222 Condensed Balance Sheet (Unaudited) (Dollars in thousands) At At 9/30/06 6/30/06 Cash and cash equivalents $257,072 $259,513 Marketable securities 18,645 5,838 Trade accounts receivable 189,487 187,502 Inventories 132,656 124,149 Other current assets 67,789 65,090 Total current assets 665,649 642,092 Property, plant and equipment (net) 138,669 137,943 Other assets, including goodwill 248,007 237,343 Total assets $1,052,325 $1,017,378 Current liabilities $211,664 $211,042 Long-term obligations 26,300 26,756 Other non-current liabilities 18,260 15,132 Shareholders’ equity 796,101 764,448 Total liabilities and shareholders’ equity $1,052,325 $1,017,378
Respironics, Inc.
CONTACT: Dan Bevevino, Vice President & CFO, Respironics, Inc.,+1-724-387-5235; Joe Calabrese, General Contact, +1-212-827-3772, or JulieTu, Analyst Information, +1-212-827-3776, both of Financial Relations Boardfor Respironics, Inc.
Web site: http://www.respironics.com/
